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Body Radiotherapy for Primary and Metastatic Lung
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Introduction: Stereotactic body radiotherapy (SBRT) has been
proposed as an alternative to surgery for the treatment of lung
cancer. The treatment of local recurrence that occurs after SBRT has
not been reported. We present surgical outcomes for local recurrence
following SBRT for primary and metastatic lung cancers.
Methods: Seven of the patients who received SBRT between 2002 and
2008 underwent salvage surgery for local recurrence. These seven
patients (two with stage I non-small cell lung cancer and five with
metastatic tumors) were operable, although they refused surgery and
chose SBRT for the first treatment as a less invasive procedure.
Results: Six of the seven patients underwent lobectomy, and the
other patient underwent segmentectomy. None of the seven patients
had direct pleural adhesion resulting from SBRT, although, in
general, radiation fibrosis occurs after radiotherapy and induces
pleural adhesion that makes surgery difficult.
Conclusions: Our study suggests that SBRT may not be the cause of
difficulties encountered during the surgical process, and surgery is a
good alternative treatment for local recurrence after SBRT. During
follow-up after SBRT, the appearance of tumor regrowth on lung
images resembled that of inflammatory changes such as radiation
pneumonitis. We suggest that close follow-ups should be mandatory
after SBRT.
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In recent years, hypofractionated stereotactic body radio-therapy (SBRT) has become available as a novel treat-
ment with low toxicity for patients with stage I non-small
cell lung cancer (NSCLC) and pulmonary metastatic tu-
mors.1–4 Especially in stage I NSCLC, the local control
rate is documented to exceed 85%.1–3 Thus, SBRT could
serve as a treatment alternative in patients who are fit to
undergo anatomic resection.
Several patterns of disease recurrence after SBRT have
been reported.1,5 These include local recurrence, regional lymph
metastasis, and distant metastasis. Resection or repeat SBRT as
salvage therapy for such local recurrences has been reported,5
but few published reports have described the therapeutic man-
agement of local recurrence after SBRT. The best therapy for
local recurrence is controversial; and therefore, in this study, we
report surgical resection for local recurrence after SBRT in a
series of patients with stage I NSCLC and pulmonary metastatic
tumors.
PATIENTS AND METHODS
Between October 2002 and December 2008, SBRT
was performed at our institution on 81 patients with stage
I NSCLC and 46 patients with 65 metastatic lesions. Of
these, six patients with stage I NSCLC and 12 patients (12
lesions in total) with metastatic tumors had local recur-
rence. Seven patients (two with stage I NSCLC and five
with metastatic tumors) underwent salvage surgery. All
seven patients were operable, although they refused sur-
gery and chose SBRT for the first treatment as it is a less
invasive procedure. Patient characteristics are summarized
in Table 1. We obtained written consent of patients or their
families for publishing their clinical data.
Stereotactic Body Radiotherapy
Patients were irradiated using stereotactic tech-
niques, the details of which are described by Onishi et al.6
In six of the seven patients, a total dose of 48 Gy was
administered at the isocenter in four fractions of 12 Gy. In
the remaining patient, a total dose of 50 Gy was adminis-
tered in 10 fractions of 5 Gy, because the tumor was
located close to the superior vena cava.
The clinical target volume marginally exceeded the
gross target volume by 0 to 5 mm. The planning target
volume comprised the clinical target volume, a 2- to 5-mm
internal margin and a 0- to 5-mm safety margin. A high
dose was concentrated on the tumor-bearing area, while
sparing the surrounding normal lung tissues using SBRT.
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A total dose of 48 or 50 Gy at isocenter was administered
with 4-MV x-rays within 20% heterogeneity in the plan-
ning target volume dose. No chemotherapy was adminis-
tered before or during SBRT. The biologic effective dose
(BED) was used in a linear-quadratic model.7 BED was
defined as nd (1  d//) with gray units, where n is the
fractionation number, d is the daily dose, and / is
assumed to be 10 for tumors (Table 1). Dose constraints
were set for the spinal cord only. The BED limit for the
spinal cord was 80 Gy (/ was assumed to be 2 Gy for
chronic spinal cord toxicity).
Follow-Ups
After SBRT, we interviewed the patients every 1 to
3 months to determine the presence or absence of symp-
toms. We also measured serum tumor markers. Lesion
characteristics were periodically examined using com-
puted tomography during follow-up visits approximately
every 3 months, and [18F]2-fluoro-2-deoxyglucose
positron emission tomography (FDG-PET) was performed
approximately every 6 months.
RESULTS
The median period of local control after SBRT was 9
months (5–18 months). The median period between SBRT and
salvage surgery was 10 months (8–25 months). The median
distance between tumor and pleura before SBRT was 14 mm
(5–30 mm). The demographic data are summarized in Tables 2
and 3 and Figure 1. Six of the seven patients underwent lobec-
tomy, including one patient with azygos vein resection and one
patient with video-assisted surgery. The other patient underwent
segmentectomy because of his age and the presence of bullous
emphysema. Lobectomy was performed for five patients with
metastatic tumors, either because they were located in the hilum
of the lung or because they were more than 4 cm in size. Two
patients did not achieve complete resection. In one of these
patients, multiple nodules in other lobes were detected during
the operation, and histologic findings of these were compati-
ble with findings of metastatic cancer. In the other patient,
the tumor invaded the chest wall. Between SBRT and
surgery, chemotherapy was administered to one of the
patients who had esophageal cancer that metastasized to
the lung. Another patient developed a postoperative pul-
monary fistula, which was treated by surgery and pleu-
rodesis. None of the seven patients had direct pleural
adhesion resulting from SBRT, although there was extensive pleu-
ral adhesion in the patient with esophageal cancer.
Histopathologic findings revealed viable tumor cells
with fibrosis in all irradiated tumors. Some of these tumors
were accompanied by necrosis. The tumors were moder-
ately cellular, and they consisted of viable tumor cells with
enlarged hyperchromatic nuclei. Because these degenera-
tive changes are common in nonirradiated tumors, the
TABLE 1. Patient Characteristics and Stereotactic Body Radiotherapy
Case
Age at
Surgery (yr) Gender Disease Histology Location
Radiation Dose
(Gy/Fractions) BED (Gy)
1 78 M Primary lung cancer Sq LUL 48/4 105.6
2 85 M Primary lung cancer Sq LUL 48/4 105.6
3 79 F Metastatic cancer (colon cancer) Ad RLL 48/4 105.6
4 72 F Metastatic cancer (colon cancer) Ad RUL 50/10 75
5 73 M Metastatic cancer (pharyngeal cancer) Sq RUL 48/4 105.6
6 63 M Metastatic cancer (esophageal cancer) Ad RUL 48/4 105.6
7 83 M Metastatic cancer (colon cancer) Ad RLL 48/4 105.6
Ad, adenocarcinoma; BED, biological effective dose; LUL, left upper lobe; RLL, right lower lobe; RUL, right upper lobe; Sq, squamous cell carcinoma.
TABLE 2. Demographic and Treatment Data
Case
Pre-SBRT
Surgery
Time Interval (mo)
Surgical Procedure
Tumor
Size
(mm)
FDG-PET
SUVmax
Distance between
Tumor Surface
and Pleura (mm)
Tumor Size
(mm)
FDG-PET
SUVmax
Between
SBRT and
Surgery
Local
Control
1 10  5 1.8 10 32  26  24 9.4 8 7 VATS lobectomy
2 15  15 7.4 10 40  30  28 12.2 19 15 Segmentectomy
3 18  10 NE 14 40  30  28 6.8 9 5 Lobectomy
4 14  14 3.2 5 30  25  25 6.0 10 9 Lobectomy with azygos vein
resection
5 10  10 2.6 28 12  10  7 3.0 19 18 Lobectomy
6 13  13 4.0 30 48  45  35 NE 25 11 Lobectomy
7 14  11 3.2 18 28  22  15 5.7 8 7 Lobectomy
FDG-PET, 18F2-fluoro-2-deoxyglucose positron emission tomography; NE, not evaluated; SBRT, stereotactic body radiotherapy; SUVmax, the maximum standardized uptake
value; VATS, video-assisted thoracic surgery.
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tumors did not especially reflect alterations secondary to
radiation therapy.
DISCUSSION
This retrospective study analyzed the possibility of
salvage therapy for patients who experience locoregional
recurrence. In all the cases, we had no difficulty in per-
forming surgery resulting from SBRT. This study, to our
knowledge, is the first report specifically describing the
outcomes in patients who undergo surgery for local recur-
rence after SBRT.
In general, radiation can damage the microcircula-
tion by hyalinization of arterioles and fibrosis,8,9 which
induces scar or fibrotic tissues. This often causes adhesion
and difficulty in curative resection and anastomosis.
All cases reported in this study had no pleural adhe-
sion due to SBRT. In one of the cases, the extensive
pleural adhesion present was probably a result of right-
sided thoracotomy for esophageal cancer. Both thoracot-
omy and video-assisted thoracic surgery could be per-
formed without resulting in severe complications. Thus,
SBRT is considered to not cause pleural adhesion or
difficulties in curative resection, when compared with
conventional radiotherapy. This might be because SBRT is
a delivery technique in which a three-dimensional orien-
tation system is used to improve targeting accuracy.
There were no obvious histopathologic alterations
attributable to radiation in any of the cases. All the tumors
were accompanied by fibrosis. Although the interval be-
tween SBRT and surgery was long enough for radiation-
induced fibrosis to develop, it was difficult to distinguish
between radiation-induced and tumor-induced fibrosis. A
few studies have also reported that radiation-induced his-
tologic alterations could not be identified in groups with
vestibular schwannoma recurrence after stereotactic radi-
ation.10,11 It has been proposed that the absence of his-
topathologic changes can be explained by (1) resistance to
global tumor radiation, (2) resistance to radiation in a
subpopulation of tumor cells followed by expansion of the
resistant clones, or (3) insufficient radiation dosage deliv-
ered to tumors.10 Recently, fibroblasts recruited into caner
tissue, called cancer-associated fibroblasts, are frequently
observed in the stroma of carcinomas and influence the
cancer progression.12,13 Cancer-associated fibroblasts in
the radiation-induced or the tumor-induced fibrosis might
contribute to tumor regrowth after SBRT. Further investi-
gations using molecular and genetic techniques are re-
quired to better understand the mechanisms of tumor
growth suppression and regrowth after SBRT.
In SBRT, a larger tumor volume or lesion originating
from colorectal cancer shows poor local control.5 All the
studied tumors were less than 20 mm in diameter before
SBRT. Nevertheless, three of the seven tumors were met-
astatic colon cancers. Once all seven irradiated tumors
resulted in disease progression, they grew in size rapidly.
Close follow-ups are essential for patients treated with
SBRT. If patients have an operable tumor that recurs
locally after SBRT, surgical resection can be considered as
the first choice of treatment, because surgical treatment in
our study was effective for salvage.
During follow-up after SBRT, differential diagnosis
of dense consolidation using routine lung computed to-
mography is very important. The appearance of dense
consolidation is a typical characteristic of radiation pneu-
monitis and fibrosis after SBRT,14 and it also implies
tumor regrowth. To distinguish between inflammatory
changes and tumor recurrence, we analyzed serum tumor
markers and FDG-PET images. The measurement of tumor
markers can be useful for the early detection of cancer.
FDG-PET usually shows accumulation resulting from
TABLE 3. Complications, Lengths of Disease-Free and Follow-Up, Survival, and Histopathologic Findings
Complications Disease Free
After Surgery
(mo)
Follow-Up After
Surgery (mo) Survival Histopathologic FindingsCase Post-SBRT Postsurgery
1 Dermatitis G1a — 32 32 Alive Viable tumor cells with fibrosis, consistent
with lung cancer
2 — Pulmonary
Fistula
2 2 Alive Viable tumor cells with fibrosis, consistent
with lung cancer
3 Pneumonitis G1a — 39 39 Alive Viable tumor cells with necrosis and fibrosis,
consistent with colon cancer
4 — — —b 25 Alive Viable tumor cells with necrosis and fibrosis,
consistent with colon cancer
5 Pneumonitis G1a — 21 21 Alive Viable tumor cells with fibrosis, consistent
with pharyngeal cancer
6 Pneumonitis G1a — —c 14 Dead Viable tumor cells with necrosis and fibrosis,
consistent with esophageal cancer
7 Pneumonitis G1a — 4d 8 Alive Viable tumor cells with necrosis and fibrosis,
consistent with colon cancer
a Common terminology criteria for adverse events version 3.0.
b Multiple pulmonary metastases.
c Invasion of adjacent chest wall.
d Regional nodal recurrence.
SBRT, stereotactic body radiotherapy.
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both inflammatory changes and recurrence in the early
period after SBRT. Hoopes et al.15 reported that moderate
FDG-PET hypermetabolic activity may persist 1 to 2 years
without evidence of recurrence. FDG-PET could be
used to assess local and, especially, distant failure
after SBRT.
Treatment strategies for local recurrence after SBRT
have not received sufficient attention. SBRT is a new and
effective treatment option for malignant tumors, especially
for stage I NSCLC. This study explored a novel therapeu-
tic strategy for stage I NSCLC—salvage surgery should be
performed immediately on detection of local recurrence
after prior SBRT treatment. The seven reported cases
occurred at a single center. Further research is required to
establish the feasibility of surgery for local recurrence
after SBRT.
In conclusion, our study suggests that SBRT may not
be the cause of difficulties in surgery for local recurrence.
FIGURE 1. Case 1 as a typical example. A, High-resolution computed tomography (CT) scan before stereotactic body
radiotherapy (SBRT) showing the tumor in the left upper lobe. B, Radiation isodose distribution. The tumor is fully en-
closed with the 100% dose line (45 Gy, red), and the nearest pleura receives 80% (36 Gy, yellow) of the total dose. C,
High-resolution CT scan 3 months after SBRT showing a scarred tumor as a partial response. D, High-resolution CT scan
7 months after SBRT showing dense consolidation considered as regrowth. E, Intraoperative photograph showing the tu-
mor (arrow) without pleural adhesion. F, Low-power field showing squamous cell carcinoma with fibrosis (hematoxylin
and eosin [HE] stain). G, High-power field showing viable tumor cells with enlarged hyperchromatic nuclei and stroma
with lymphocyte infiltration (HE stain).
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Because tumor regrowth after SBRT is thought to occur at
a rapid rate, close follow-ups should be mandatory for
patients treated with SBRT.
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